详细说明
Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. When Folic Acid-Bovine Serum Albumin was coated at 5 μg/mL (100 μL/well), the concentration of rhFOLR-2 that produces 50% of the optimal binding response was found to be approximately 0.2 -1 nM.
Source
Chinese Hamster Ovary cell line, CHO-derived Gln22-His228, with a C-terminal 6-His tag
Accession #
N-terminal Sequence
AnalysisNo results obtained: Gln22 predicted
Predicted Molecular Mass
25.4 kDa
SDS-PAGE
25-40 kDa, reducing conditions
5697-FR |
| |
Formulation Lyophilized from a 0.2 μm filtered solution in PBS. | ||
Reconstitution Reconstitute at 100 μg/mL in PBS. | ||
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: FOLR2
Folate Receptor 2 (FOLR2), also known as Folate Receptor beta, is a 38 kDa protein that mediates the cellular uptake of folic acid and reduced folates. Dietary folates are required for many key metabolic processes including nucleotide and methionine synthesis, the interconversion of glycine and serine, and histidine breakdown (1, 2). Mature FOLR2 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage (3, 4). Human FOLR2 shares 83% amino acid sequence identity with mouse and rat FOLR2. FOLR2 is predominantly expressed in placenta, cells of the neutrophilic lineage, and some CD34+ hematopoietic progenitor cells (4 - 6). It is upregulated on myeloid leukemias, head and neck squamous cell carcinomas, and several nonepithelial cancers (3, 5, 7). It is also upregulated on macrophages and monocytes at chronic inflammatory sites including rheumatoid arthritis synovium and glioblastoma (8 - 10). FOLR2 knockout mice do not show gross morphological defects, but they exhibit increased sensitivity to arsenate-induced teratogenicity (11, 12).
References:
Fowler, B. et al. (2001) Kidney Int. 59:S-221.
Kelemen, L.E. (2006) Int. J. Cancer 119:243.
Shen, F. et al. (1994) Biochemistry 33:1209.
Ratnam, M. et al. (1989) Biochemistry 28:8249.
Ross, J.F. et al. (1999) Cancer 85:348.
Reddy, J.A. et al. (1999) Blood 93:3940.
Ross, J.F. et al. (1994) Cancer 73:2432.
Nakashima-Matsushita, N. et al. (1999) Arthritis Rheum. 42:1609.
van der Heijden, J.W. et al. (2009) Arthritis Rheum. 60:12.
Nagai, T. et al. (2009) Cancer Immunol. Immunother. Feb 24 epub.
Piedrahita, J.A. et al. (1999) Nat. Genet. 23:228.
Wlodarczyk, B. et al. (2001) Toxicol. Appl. Pharmacol. 177:238.
Long Name:
Folate Receptor 2
Entrez Gene IDs:
2350 (Human); 14276 (Mouse); 293154 (Rat)
Alternate Names:
beta-HFR; FBP; FBP/PL-1; folate receptor 2 (fetal); Folate receptor 2; folate receptor beta; folate receptor, beta; Folate receptor, fetal/placental; folate-binding protein, fetal/placental; FOLR2; FR-beta; FR-P3; Placental folate-binding protein